1. Introduction {#s0005}
===============

Polycystic ovary syndrome (PCOS) is a common disease of obstetrics and gynecology. It was mainly caused by anovulation endocrine disorders with clinical manifestations of diversity, including irregular menstruation, infertility, and so on. According to statistics ([@b0105], [@b0055], [@b0120]), the incidence of polycystic ovary syndrome in women of childbearing age was as high as 10% and it brings seriously negative affect to the healthy and family life of patients. Drug treatment is the common method of clinical treatment. Analysis on effects of human chorionic gonadotropin combined with clomiphene on serum E~2~, FSH, LH and PRL levels during the treatment was conducted in this study. The results are reported as follows.

2. Materials and methods {#s0010}
========================

2.1. General information {#s0015}
------------------------

90 patients with polycystic ovarian syndrome treated from January 2015 to March 2016 were randomly and evenly divided into control group and observation group. Patient enrollment criteria: patients clinically diagnosed with polycystic ovary syndrome, not using hormonal drugs recently. Exclusion criteria: patients with liver and kidney dysfunction. This study was agreed by the patients and approved by our hospital ethical committee. There were no significant difference between the two groups in general clinical materials, including age, weight, height, infertility type and BMI, and so on (*p* \> 0.05), and it was strongly comparable. Data are shown in [Table 1](#t0005){ref-type="table"}.

2.2. Methods {#s0020}
------------

Treatment in the control group: Patients were only treated with clomiphene. Clomiphene was given orally with the dose of 100 mg/d (specification: 50 mg × 20particle/box, approval number: national medicine approved number H31021107, manufacturer: Shanghai Hengshan Pharmaceutical Co., Ltd.). The treatment was stopped after 12 d of continuous medicine taken. It would be extended to three menstrual cycles, if the patient was not pregnant. Treatment in the observation group: Clomiphene was combined with human chorionic gonadotropin in the treatment. Clomiphene was given orally with the dose of 100 mg/d. The diameter of follicular was observed and if it is larger than 18 mm, intramuscular injection of 100 mg human chorionic gonadotropin was given. If the patient was not pregnant, the treatment was continued for three menstrual cycles.

Serum E~2~, FSH, LH and PRL levels was determined by immune analyzer after patients in the two groups taking drug for 3 menstrual cycles.

2.3. Observed indicators {#s0025}
------------------------

### 2.3.1. E~2~, FSH, LH and PRL were chosen as observed indicators {#s0030}

Venous blood was extracted from all patients at 9 am in their fasting state. After centrifuge separation, the separated serum was placed in a thermostat of −40 °C for storage. Enzyme linked immunosorbent assay (ELIA) method is applied to determine the levels of E~2~, FSH, LH, PRL in serum.

### 2.3.2. Clinical curative effect criterion ([@b0015], [@b0080], [@b0005], [@b0115], [@b0090]) {#s0035}

According to the menstrual recovery degree, curative effects could be divided into the following four grades. Healing-Menstruation returned to normal level during treatment or one year later, and the patient got pregnant successfully. Excellent-Menstruation returned to normal level during treatment or one year later, but the patient were failed to get pregnant. Improved-The function of ovulation was normal, but the amount of menstruation is less than normal during treatment or within one year. Failure-menstrual cycle was serious delayed and no ovulation was found. Total effective rate = (Healing cases + Excellent cases + Improved cases)/total cases × 100.00%.

2.4. Statistical analysis {#s0040}
-------------------------

Data were analyzed using SPSS 18.0. Data were represented as mean ± standard deviation ($\overline{x} \pm s$). Measurement data were compared using *T*-test. Count data were compared using chi-square (*χ*^2^) test. Grade data were compared using rank sum test. Result of *P* \< 0.05 was considered to be statistically significant.

3. Results {#s0045}
==========

3.1. Changes of E2, FSH, LH, PRL levels in the two groups after treatment {#s0050}
-------------------------------------------------------------------------

Serum E~2~, FSH, LH and PRL levels in two groups decreased significantly after treatment. The difference is statistical significant (*P* \< 0.05. The levels of E~2~, FSH, LH and PRL in observation group were lower than that in the control group and the difference was statistical significant (*P* \< 0.05). Detail data is listed in [Table 2](#t0010){ref-type="table"}.

3.2. Evaluation of clinical curative effects in the two groups {#s0055}
--------------------------------------------------------------

The total effective rate was 64.44% in control group and 93.33% in observation group. The difference of clinical curative effects in the two groups was statistically significant (*P* \< 0.05). Detail data is listed in [Table 3](#t0015){ref-type="table"}.

3.3. Comparison of adverse reactions in the two groups {#s0060}
------------------------------------------------------

Different degrees of adverse reactions were found in both groups during treatment, such as nausea, vomiting, anorexia, liver dysfunction and ovarian hyper-stimulation. There were 2 cases of nausea, 2 cases of vomiting, 3 cases of anorexia, 1 case of liver dysfunction and 2 cases of ovarian hyper-stimulation from the 45 patients in control group. The total incidence of adverse reactions was 17.78% (8/45). There were 1 case of nausea, 1 case of vomiting, 1 case of anorexia, no liver dysfunction and no ovarian hyper-stimulation from the 45 patients in observation group. The total incidence of adverse reactions was 6.67% (3/45). The total incidence of adverse reactions of the observation group was significantly higher than that of the control group and the difference was not statistically significant (*P* \> 0.05).

4. Discussion {#s0065}
=============

At present, with the accelerating pace of social life, more and more women suffer from polycystic ovary syndrome, a common clinical gynecological syndrome ([@b0140], [@b0025], [@b0010], [@b0125], [@b0135], [@b0045]). It's a type of metabolic syndrome with clinical features like endocrine disorder, high androgen and chronic anovulation. The infertility symptom causes various problems to the patients and their family and affects their happiness severely. The main treatments for polycystic ovary syndrome in practice are behavioral therapy, surgery and medicine, supplemented with proper adjustments to diet structure. Among them, medical therapy is the most often applied treatment ([@b0050], [@b0075], [@b0110], [@b0100], [@b0030]). Clomiphene is a hormone-like biological agent. It can promote the secretion of gonadotropin from hypothalamus. With estrogen index improved, resistance to androgen is enhanced and hypothalamic releasing of GnRH is increased, then the LH and FSH levels in serum is raised. However, a number of clinical practice ([@b0145], [@b0035], [@b0060], [@b0040], [@b0070]) show that due to the anti-estrogen effects of clomiphene, endometrial gets thinner and sperm pass rate gets lower. After the treatment, the pregnancy rate is low and the miscarriage rate is high. Human chorionic gonadotropin is a kind of glycoprotein secreted by placental trophoblast cells. It can accelerate the secretion of androstenedione and progesterone. In addition, it is similar to LH with respect to property and activity and can improve the ovulation rate partly ([@b0065], [@b0095], [@b0085]). The combination of clomiphene and human chorionic gonadotropin can effectively prevent excessive luteinizing and promote follicle rupture ovulation. This study investigated the effects of human chorionic gonadotropin combined with clomiphene on serum E~2~, FSH, LH and PRL levels in patients with polycystic ovarian syndrome based on 90 patients.

The study shows that the serum E~2~ level in patients treated with clomiphene alone decreased from 196.23 ± 43.26 pmol/L before treatment to 176.23 ± 30.23 pmol/L, while the decreased level was still higher than that in patients treated with clomiphene combined with human chorionic gonadotropin (158.40 ± 32.07 pmol/L). Serum FSH, LH and PRL levels in patients treated by both the two methods showed a downward trend after the treatment, while the levels in patients treated with clomiphene combined with human chorionic gonadotropin were higher than that in patients treated with clomiphene alone. It suggested that human chorionic gonadotropin can significantly reduce serum E~2~, FSH, LH and PRL levels. This result is consistent to the reported results ([@b0020], [@b0130]). Out of the 45 patients treated with clomiphene alone, 29 of them were effectively treated. The total effective rate was 64.44%. In contrast, 42 patients were effectively treated, from the total 45 patients treated with the combinative method. Its total effective rate was 93.33%, significantly higher than that of the former one. Human chorionic gonadotropin significantly improved the clinical curative effect. Different degrees of adverse reactions were found in all patients, such as nausea, vomiting, anorexia and liver dysfunction. There were 8 patients with adverse reactions from 45 patients treated with clomiphene alone and the total incidence of adverse reactions was 17.78%. There were 3 patients with adverse reactions from 45 patients treated with clomiphene combined with human chorionic gonadotropin and the total incidence of adverse reactions was 17.78%. No liver dysfunction and ovarian hyper-stimulation were found.

Combined use of human chorionic gonadotropin and clomiphene for the treatment of polycystic ovary syndrome can significantly reduce levels of E~2~, FSH, LH and PRL in serum, improve clinical curative effect and reduce the incidence of adverse reactions. Human chorionic gonadotropin has high application value on the treatment of polycystic ovary syndrome.
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###### 

Comparison of general clinical materials in two groups.

  Materials               Control group (*n* = 45)   Observation group (*n* = 45)   *t*/*χ*^2^ Value   *P* Value
  ----------------------- -------------------------- ------------------------------ ------------------ -----------
  Average age (years)     35.46 ± 4.12               35.02 ± 4.57                   0.4797             0.6326
  Average height (cm)     168.23 ± 3.42              167.09 ± 4.18                  1.4160             0.1603
  Average weight (kg)     64.18 ± 4.02               65.04 ± 3.17                   1.1269             0.2629
                                                                                                       
  Infertility type                                                                                     
   Primary infertility    33 (73.33)                 30 (66.67)                     3.7479             0.0529
  Secondary infertility   12 (26.67)                 15 (33.33)                                        
                                                                                                       
  BMI (kg/cm^2^)          25.02 ± 2.69               25.97 ± 2.49                   1.7386             0.0856

###### 

Changes of E~2~, FSH, LH and PRL levels in the two groups before and after treatment.

  Indicators      Control group (*n* = 45)   Observation group (*n* = 45)                    
  --------------- -------------------------- ------------------------------ ---------------- ----------------
  E~2~ (pmol/L)   196.23 ± 43.26             176.23 ± 30.23                 197.02 ± 45.16   158.40 ± 32.07
  FSH (u/L)       7.46 ± 1.48                6.72 ± 1.21                    7.39 ± 1.50      5.46 ± 1.09
  LH (u/L)        13.52 ± 2.14               10.36 ± 2.01                   13.46 ± 2.42     8.45 ± 1.75
  PRL (ng/L)      28.74 ± 11.02              16.12 ± 5.04                   28.19 ± 12.91    14.46 ± 3.72

###### 

Evaluation of clinical curative effects in the two groups \[*n* (%)\].

  Groups                         Healing      Excellent    Improved     Failure      Total effective rate
  ------------------------------ ------------ ------------ ------------ ------------ ----------------------
  Control group (*n* = 45)       3 (6.67)     12 (26.67)   14 (31.10)   16 (35.56)   29 (64.44)
  Observation group (*n* = 45)   11 (24.44)   19 (42.22)   12 (26.67)   3 (6.67)     42 (93.33)
  *χ*^2^ Value                                                                       11.2750
  *P* Value                                                                          0.0008
